Pharmaceutical companies in China are reporting that they have been able to import some drugs over the past week with tariff ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Merck & Co., Inc. (MRK) is currently at $82.84, up $3.00 or 3.76% --Would be highest close since April 3, 2025, when it closed at $86.39 --On pace for largest percent increase since March 27, 2024, ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data ...

Major drug companies are beginning to deliver their first-quarter readouts to Wall Street analysts, revealing their ...

A modified FLOT regimen (fluorouracil, oxaliplatin, and docetaxel; TFOX) outperformed a standard chemotherapy triplet for the ...

Early identification of individuals at a high risk for MASLD could “profoundly transform” intervention strategies, experts say.

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Pharmaceutical companies in China report importing drugs with tariff exemptions, indicating possible flexibility from Chinese ...

Major stock indexes held firm in the stock market today after three days of bullish gains. Tesla spiked 9% and Nvidia led the ...